Name: Neramexane
Synonyms: MRZ 2/579
Chemical Name: 1,3,3,5,5-pentamethylcyclohexanamine
Therapy Type: Small Molecule (timeline)
Target Type: Other Neurotransmitters (timeline)
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Discontinued)
Company: Forest Laboratories, Inc., Merck
Approved for: None


Similar to memantine, neramexane is an NMDA receptor channel blocker with moderate affinity. It displays voltage dependency, and rapid unblocking kinetics (Gilling et al., 2007). Neramexane also has been shown to block acetylcholine-evoked responses by antagonizing the alpha-9 alpha-10 nicotinic acetylcholine receptor (Plazas et al., 2007).


No Available Comments

Make a Comment

To make a comment you must login or register.


Paper Citations

  1. . A novel class of amino-alkylcyclohexanes as uncompetitive, fast, voltage-dependent, N-methyl-D-aspartate (NMDA) receptor antagonists--in vitro characterization. J Neural Transm. 2007;114(12):1529-37. Epub 2007 Aug 31 PubMed.
  2. . Inhibition of the alpha9alpha10 nicotinic cholinergic receptor by neramexane, an open channel blocker of N-methyl-D-aspartate receptors. Eur J Pharmacol. 2007 Jul 2;566(1-3):11-9. PubMed.

Further Reading

No Available Further Reading